stockrow
Friday 6 November 2026
Export EVH’s income statement to Excel — free account
Evolent Health, Inc
EVH Healthcare Health Information Services
Evolent Health, Inc’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 26.6% from fiscal 2024.
- Revenue
- +51.3%
- EPS
- +12.5%
- Free cash flow
- +179.8%
- Total debt
- −8.09%
Quarter to September 2026, against a year earlier
4.60
0.06
+1.32%
Follow EVH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.24 | 0.14 | 0.29 | 0.17 | |
P/FCF ratio |
96.07 | 182.90 | 25.06 | 10.77 | |
P/Operating CF |
9.36 | (259.29) | (65.50) | 14.96 | |
P/B ratio |
1.10 | 0.64 | 1.59 | 1.06 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.67 | 0.56 | 0.69 | 0.52 | |
EV/EBITDA |
10.56 | 9.81 | 14.39 | 12.11 | |
EV/Operating CF |
32.16 | 31.92 | 26.47 | 18.64 | |
EV/FCF |
262.75 | 761.74 | 59.07 | 32.99 | |
Quick Ratio |
1.27 | 1.26 | 1.19 | 1.22 | |
Current Ratio |
1.31 | 1.32 | 1.24 | 1.26 | |
Net Debt/EBITDA |
20.35 | 54.43 | 51.48 | 0.00 | |
Debt/Assets |
51.10% | 51.81% | 49.01% | 49.41% | |
Debt/Equity |
2.34 | 2.46 | 2.52 | 2.60 | |
Asset Turnover |
0.84 | 0.83 | 0.95 | 1.06 | |
Operating CF/Net income |
(0.11) | 0.04 | 0.33 | (1.12) | |
Capex/Depreciation |
(0.02) | (0.25) | (0.27) | 0.00 | |
Interest Coverage |
(21.47) | (0.63) | (0.57) | (0.36) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.50% | 14.67% | 10.55% | 10.08% | |
Intangible Assets out of Total Assets |
0.67 | 0.67 | 0.63 | 0.63 | |
Share Based Compensation of Revenue |
0.51% | 2.15% | 2.33% | 2.04% | |
Graham Net Nets |
(2.14) | (3.84) | (1.60) | (2.46) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(128.75%) | (208.77%) | (84.32%) | (130.09%) | |
Free Cash Flow Yield |
1.04% | 0.55% | 3.99% | 9.29% | |
Revenue per Share |
4.10 | 4.43 | 5.80 | 6.42 | |
Operating CF per Share |
0.43 | (0.01) | (0.08) | 0.23 | |
Capex per Share |
(0.07) | (0.06) | (0.06) | (0.06) | |
Free Cash Flow per Share |
0.36 | (0.07) | (0.14) | 0.17 | |
Cash per Share |
1.56 | 1.48 | 1.23 | 1.37 | |
Shareholders Equity per Share |
3.64 | 3.54 | 3.41 | 3.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.64 | 3.54 | 3.41 | 3.30 | |
Free Cash Flow |
41.04 | (7.39) | (16.16) | 19.17 | |
Working Capital |
121.11 | 120.78 | 117.68 | 127.18 | |
Capital Expenditures |
(7.76) | (6.41) | (6.85) | (7.21) | |
Net Current Asset Value |
(977.67) | (980.44) | (978.16) | (972.19) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
362.27 | 372.33 | 403.94 | 414.67 | |
Average Payables |
77.90 | 60.41 | 54.14 | 55.01 | |
Average Assets |
2,221.82 | 2,266.15 | 2,216.71 | 2,207.81 | |
Average Common Equity |
708.23 | 665.96 | 639.61 | 607.54 |
Columns are period end dates · fundamentals updated 5 Nov 2026